Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression
NCT02201303
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Infections, Respiratory Syncytial Virus
Interventions
DRUG:
Danirixin
OTHER:
CXCL1
Sponsor
GlaxoSmithKline